Bimekizumab bests Guselkumab in psoriatic arthritis, reveals new study
Bimekizumab bests Guselkumab in psoriatic arthritis, reveals new study published in the Rheumatology and Therapy. Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis (PsA) who […]